Anna M.J. Thijs

496 total citations
9 papers, 143 citations indexed

About

Anna M.J. Thijs is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Reproductive Medicine. According to data from OpenAlex, Anna M.J. Thijs has authored 9 papers receiving a total of 143 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Cardiology and Cardiovascular Medicine, 4 papers in Oncology and 4 papers in Reproductive Medicine. Recurrent topics in Anna M.J. Thijs's work include Ovarian cancer diagnosis and treatment (4 papers), Renal cell carcinoma treatment (2 papers) and Cardiac tumors and thrombi (2 papers). Anna M.J. Thijs is often cited by papers focused on Ovarian cancer diagnosis and treatment (4 papers), Renal cell carcinoma treatment (2 papers) and Cardiac tumors and thrombi (2 papers). Anna M.J. Thijs collaborates with scholars based in Netherlands, United Kingdom and United States. Anna M.J. Thijs's co-authors include Winette T.A. van der Graaf, Carla M.L. van Herpen, Gerard A. Rongen, Anneke Geurts‐Moespot, Fred C.G.J. Sweep, Paul Smits, Viviènne Verweij, Jurgen M.J. Piek, Jeanne Pertijs and Anja van de Stolpe and has published in prestigious journals such as Hypertension, International Journal of Cancer and Journal of Hypertension.

In The Last Decade

Anna M.J. Thijs

8 papers receiving 142 citations

Peers

Countries citing papers authored by Anna M.J. Thijs

Since Specialization

Citations

This map shows the geographic impact of Anna M.J. Thijs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna M.J. Thijs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna M.J. Thijs more than expected).

Fields of papers citing papers by Anna M.J. Thijs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna M.J. Thijs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna M.J. Thijs. The network helps show where Anna M.J. Thijs may publish in the future.

Co-authorship network of co-authors of Anna M.J. Thijs

This figure shows the co-authorship network connecting the top 25 collaborators of Anna M.J. Thijs. A scholar is included among the top collaborators of Anna M.J. Thijs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna M.J. Thijs. Anna M.J. Thijs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosing 2025 ·International Journal of Cancer ·(unknown), Didier Meulendijks, (unknown), (unknown), Geert‐Jan Creemers, (unknown), (unknown), Lieke H. J. Simkens, Birgit Deiman, Hans Gelderblom, Henk‐Jan Guchelaar, Anna M.J. Thijs, Maarten J. Deenen	0
2	Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol 2023 ·Heliyon ·(unknown), (unknown), Anna M.J. Thijs, Hans M. Westgeest, H.P.M. Smedts, M. Caroline Vos, Mathilde Jalving, Christianne Lok, Ingrid Boere, (unknown), Petronella B. Ottevanger, Anneke M. Westermann, Constantijne H. Mom, Roy Lalisang, Sandrina Lambrechts, Ruud L.M. Bekkers, Jurgen M.J. Piek	2
3	The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectives 2022 ·Gynecologic Oncology Reports ·(unknown), (unknown), (unknown), M. Caroline Vos, Anna M.J. Thijs, Joanne A. de Hullu, Petronella B. Ottevanger, Christianne Lok, Jurgen M.J. Piek	4
4	The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis 2021 ·Gynecologic Oncology ·(unknown), (unknown), Anna M.J. Thijs, Hans M. Westgeest, Ingrid Boere, Sandrina Lambrechts, Anja van de Stolpe, Ruud L.M. Bekkers, Jurgen M.J. Piek	28
5	Efficacy of Anti-Estrogen Therapy in Estrogen Receptor Positive High-Grade Serous Ovarian Carcinoma: A Systematic Review 2020 ·(unknown), (unknown), (unknown), Anja van de Stolpe, Steven L. Bosch, Anna M.J. Thijs, Ruud L.M. Bekkers, Jurgen M.J. Piek	2
6	Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension 2015 ·Journal of Hypertension ·Anna M.J. Thijs, Carla M.L. van Herpen, Viviènne Verweij, Jeanne Pertijs, Petra H.H. van den Broek, Winette T.A. van der Graaf, Gerard A. Rongen	24
7	Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle 2014 ·Targeted Oncology ·Anna M.J. Thijs, Saloua El Messaoudi, (unknown), Alfons C. Wouterse, Viviènne Verweij, (unknown), Carla M.L. van Herpen, Winette T.A. van der Graaf, L. Noyez, Gerard A. Rongen	4
8	Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans 2013 ·Hypertension ·Anna M.J. Thijs, Carla M.L. van Herpen, Fred C.G.J. Sweep, Anneke Geurts‐Moespot, Paul Smits, Winette T.A. van der Graaf, Gerard A. Rongen	45
9	Temsirolimus for metastatic desmoplastic small round cell tumor 2010 ·Pediatric Blood & Cancer ·Anna M.J. Thijs, Winette T.A. van der Graaf, Carla M.L. van Herpen	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact